BSE: 543399 | NSE: TARSONS | Plastic Products | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Tarsons Products Ltd is a average quality company.
The key valuation ratios of Tarsons Products Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Tarsons Products Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0% | 31.6% | 27.4% | 37.2% | 35.3% | 19% | 10.2% | - |
| Value Creation Index ⓘ | NA | NA | NA | NA | 1.3 | 1.0 | 1.7 | 1.5 | 0.4 | -0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 179 | 176 | 229 | 301 | 283 | 277 | 293 |
| Sales YoY Gr. | - | NA | NA | NA | NA | -1.6% | 30.1% | 31.4% | -5.8% | -2.1% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 7.5 | 7.4 | 13.2 | 18.4 | 14.4 | 8.9 | 9.1 |
| YoY Gr. | - | NA | NA | NA | NA | -1.2% | 77.9% | 39.5% | -21.8% | -38.4% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 0 | 26.6 | 37.3 | 48 | 92.1 | 107 | 116.6 | 118.2 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 38.3 | 39.4 | 67.3 | 98.1 | 76.7 | 47.3 | 48 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 0 | 51.3 | 64.2 | 68.2 | 83.5 | 75.6 | 105 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 1.3 | 0.6 | 0.5 | 0.3 | 1.5 | 2.4 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 9.2% | 6.6% | -2.1% | ||||
| Adj EPS ⓘ | NA | 3.4% | -12.4% | -38.4% | ||||
| BVPSⓘ | NA | 34.4% | 34.4% | 9% | ||||
| Share Price | - | - | -12.6% | -18.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 0 | 28.3 | 23.7 | 30.5 | 26.7 | 14.5 | 8 | 7.7 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 40.1 | 38.9 | 45.1 | 50.8 | 45.7 | 37.3 | 33.2 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 21.4 | 22.4 | 29.4 | 32.6 | 27.1 | 17.1 | 16.5 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0.5 | 0.2 | 0.1 | 0 | 0.2 | 0.4 | 0.2 |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 371 | 343 | 372 | 543 | 706 | 109 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 172 | 127 | 127 | 187 | 218 | -1 |
No data to display
Return on Equity has declined versus last 3 years average to 7.70%
Sales growth has been subdued in last 3 years 6.60%
Net Profit has been subdued in last 3 years -12.39%
Sales growth is not so good in last 4 quarters at 7.70%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 9.1 | 6.5 |
| TTM Sales (₹ Cr.) | 293 | 352 |
| BVPS (₹.) ⓘ | 118.2 | 115.4 |
| Reserves (₹ Cr.) ⓘ | 629 | 603 |
| P/BV ⓘ | 3.48 | 3.56 |
| PE ⓘ | 45.35 | 63.32 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 377.75 / 573.95 |
| All Time Low / High (₹) | 377.75 / 928.65 |
| Market Cap (₹ Cr.) | 2,188 |
| Equity (₹ Cr.) | 10.6 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Sales | 179 | 176 | 229 | 301 | 283 | 277 |
| Operating Expenses ⓘ | 107 | 108 | 126 | 148 | 154 | 174 |
| Manufacturing Costs | 24 | 23 | 27 | 36 | 31 | 31 |
| Material Costs | 51 | 49 | 62 | 63 | 65 | 73 |
| Employee Cost | 16 | 20 | 24 | 31 | 34 | 39 |
| Other Costs ⓘ | 16 | 16 | 12 | 18 | 24 | 31 |
| Operating Profit ⓘ | 72 | 68 | 103 | 153 | 129 | 103 |
| Operating Profit Margin (%) | 40.1% | 38.9% | 45.1% | 50.8% | 45.7% | 37.3% |
| Other Income ⓘ | 6 | 5 | 6 | 8 | 12 | 14 |
| Interest ⓘ | 7 | 6 | 3 | 4 | 4 | 10 |
| Depreciation ⓘ | 15 | 14 | 14 | 22 | 29 | 38 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 56 | 53 | 92 | 135 | 109 | 69 |
| Tax ⓘ | 17 | 13 | 24 | 34 | 28 | 18 |
| Profit After Tax | 39 | 41 | 69 | 101 | 81 | 51 |
| PAT Margin (%) | 21.8% | 23.0% | 30.1% | 33.5% | 28.5% | 18.5% |
| Adjusted EPS (₹) | 7.7 | 7.7 | 13.5 | 18.9 | 15.2 | 9.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 21% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 135 | 198 | 244 | 490 | 569 | 620 | ||||
| Share Capital ⓘ | 0 | 0 | 0 | 11 | 11 | 11 | ||||
| Reserves ⓘ | 135 | 197 | 244 | 479 | 559 | 610 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 55 | 25 | 26 | 10 | 81 | 204 | ||||
| Long Term Debt | 19 | 6 | 3 | 9 | 81 | 102 | ||||
| Short Term Debt | 36 | 19 | 23 | 1 | 0 | 102 | ||||
| Trade Payables | 2 | 6 | 6 | 13 | 10 | 8 | ||||
| Others Liabilities ⓘ | 79 | 93 | 115 | 160 | 220 | 292 | ||||
| Total Liabilities ⓘ | 271 | 321 | 392 | 673 | 879 | 1,125 | ||||
Fixed Assets | ||||||||||
| Gross Block | 104 | 121 | 163 | 253 | 316 | 382 | ||||
| Accumulated Depreciation | 15 | 29 | 42 | 64 | 92 | 130 | ||||
| Net Fixed Assetsⓘ | 89 | 92 | 120 | 189 | 225 | 252 | ||||
| CWIP ⓘ | 7 | 19 | 22 | 32 | 119 | 267 | ||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Inventories | 46 | 49 | 47 | 82 | 114 | 105 | ||||
| Trade Receivables | 45 | 38 | 47 | 65 | 66 | 72 | ||||
| Cash Equivalents | 1 | 26 | 3 | 86 | 60 | 10 | ||||
| Others Assetsⓘ | 83 | 97 | 152 | 219 | 295 | 420 | ||||
| Total Assets ⓘ | 271 | 321 | 392 | 673 | 879 | 1,125 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 51 | 64 | 68 | 83 | 76 | 105 |
| PBT ⓘ | 56 | 53 | 92 | 135 | 109 | 69 |
| Adjustment ⓘ | 21 | 20 | 16 | 24 | 28 | 47 |
| Changes in Working Capital ⓘ | -9 | 6 | -16 | -42 | -36 | 7 |
| Tax Paid ⓘ | -17 | -15 | -24 | -33 | -24 | -18 |
| Cash Flow From Investing Activity ⓘ | -34 | -25 | -64 | -138 | -179 | -296 |
| Capex | -34 | -26 | -62 | -132 | -189 | -184 |
| Net Investments | 0 | 0 | 0 | -7 | 7 | -4 |
| Others ⓘ | 0 | 1 | -2 | 1 | 3 | -108 |
| Cash Flow From Financing Activityⓘ | -18 | -14 | -27 | 130 | 85 | 136 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 150 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -30 | -11 | -7 | 10 | 90 | 44 |
| Interest Paid ⓘ | -6 | -5 | -5 | -4 | -5 | -10 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 17 | 2 | -15 | -26 | -1 | 102 |
| Net Cash Flow ⓘ | 0 | 25 | -23 | 75 | -18 | -55 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 28.8 | 24.35 | 31.17 | 27.42 | 15.24 | 8.62 | ||||
| ROCE (%) | 31.57 | 27.35 | 37.22 | 35.28 | 19 | 10.19 | ||||
| Asset Turnover Ratio | 0.66 | 0.59 | 0.64 | 0.56 | 0.36 | 0.28 | ||||
| PAT to CFO Conversion(x) | 1.31 | 1.56 | 0.99 | 0.82 | 0.94 | 2.06 | Working Capital Days | |||
| Receivable Days | 91 | 86 | 68 | 68 | 84 | 91 | ||||
| Inventory Days | 95 | 99 | 76 | 78 | 127 | 145 | ||||
| Payable Days | 14 | 30 | 35 | 55 | 63 | 45 | ||||
Tarsons Products is an Indian labware company engaged in the designing, development, manufacturing and marketing of ‘consumables’, ‘reusables’ and ‘others’ including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations (CROs), Diagnostic companies and hospitals. It manufactures a range of quality labware products which helps advance scientific discovery and improve healthcare. The company’s product portfolio is classified into three key categories which include consumables, reusables, and others. ‘Consumables’ category includes products such as centrifuge ware, cryogenic ware, liquid handling, PCR consumables and petri dish, transfer pipettes and others. ‘Reusables’ category includes products such as bottles, carboys, beakers, measuring cylinders and tube racks. ‘Others’ category includes benchtop instrumentation such as vortex shakers, centrifuges pipettors and others.
The company caters to a diverse range of end customers across various sectors which include research organizations, academic institutions, pharmaceutical companies, CROs, diagnostic companies, and hospitals. Some of its end customers include customers such as Indian Institute of Chemical Technology, National Centre for Biological Sciences across academic institutes and research organizations; Dr Reddy's Laboratories, Enzene Biosciences across pharmaceutical sectors; Syngene International, Veeda Clinical Research across CROs; and Molbio Diagnostics, Agappe Diagnostic, Metropolis Healthcare, Dr. Lal Path Labs, Mylab Life Solutions across other sectors such as diagnostics. It distributes its products to these end customers on a pan-India basis through its authorised distributors. It has long-standing relationships with its end customers as well as distributors, which it has achieved by aligning its offerings with their business needs and through the support of an on-ground sales and marketing team.
Business area of the company
The company presently manufactures disposable plastic labware, centrifuge ware, cryo labware, liquid handling system and instruments.
Major events and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
